Near-Zero-Fluoroscopy Ablation of Atrial Fibrillation Without ICE or Non-Fluoroscopic Tracking Systems: Findings From...

Catheter ablation is the key element of rhythm control in atrial fibrillation (AF), yet its reliance on fluoroscopy exposes patients and operators to radiation. A fluoroscopy-free procedure is possible using intracardiac echocardiography (ICE), but due to high cost, the learning curve, and added procedural steps, ICE is rarely used in Europe. Similarly, non-fluoroscopic tracking systems (NCTS) like MediGuide for near-zero fluoroscopy ablation have fallen out of favor. The SHORT LOOK study evaluates the efficiency and safety of a streamlined near-zero fluoroscopy workflow for first-time pulmonary vein isolation (PVI) based solely on advanced 3D mapping and an ultra-low-dose fluoroscopy protocol. The aim was to determine whether near-zero fluoroscopy ablation can be achieved using conventional techniques, enabling broader adoption in modern electrophysiology labs.

The SHORT LOOK registry is a single-center, investigator-initiated prospective standard-of-care study enrolling consecutive patients undergoing first-time PVI for AF. A total of 450 patients were included in the final analysis. The workflow used a 3D mapping system (CARTO3, J&J MedTec) with an ultra-low-dose fluoroscopy protocol, without adjunctive technologies. Baseline assessments included medical history, physical examination, labs, ECG, EQ-VAS, and echocardiography. The primary efficacy endpoint was median fluoroscopy time; the primary safety endpoint was a composite of procedure-related death or cardiovascular, neurological, or vascular events. Secondary endpoints included 1-year freedom from atrial arrhythmia > 30 s, skin-to-skin time, fluoroscopy dose, and proportion of procedures with fluoroscopy < 1 min. Patients were followed up for 1 year.

The SHORT LOOK cohort (n = 450) achieved a median procedural time of 57 min, with median fluoroscopy time of 26 s and dose of 9.1 µGy*m². The complication rate was < 1% and no major adverse events occurred. Follow-up revealed that for paroxysmal atrial fibrillation, 86.1% were AT/AF-free at 3 months, decreasing to 82.6% at 12 months, while for persistent atrial fibrillation, the rates were 77.3% and 71.7%, respectively, confirming sustained rhythm control. EQ-VAS analyses revealed a significant improvement in health-related quality of life from baseline (p < 0.05). Compared to a historical NCTS group, our workflow leads to similarly low fluoroscopy times and radiation doses.

The streamlined workflow for initial atrial fibrillation ablation, which nearly eliminates fluoroscopy, demonstrates a significant reduction in both fluoroscopy time and radiation dose. This approach is feasible in any electrophysiology laboratory and offers a practical method for performing rapid, safe, and effective AF ablations while maintaining minimal radiation exposure-all without the need for additional adjunctive technologies.